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Objective: To evaluate the use of serodiagnosis for tuberculosis and leprosy using mycobacterial antigen 38 kDa, with
kits from Omega laboratories, to detect IgG by enzyme immunoassay (EIA).
Methods: The study population consisted of 58 patients with evidence of tuberculous infection (culture of
Mycobacterium tuberculosis complex or microscopic evidence). of whom 23 had pulmonary and 35 had extrapulmonary
disease. There were six subjects who had recently been treated for tuberculosis, 11 patients on treatment for leprosy
and 137 patients suspected of having tuberculosis on clinical or radiologic grounds (without laboratory evidence). A
control group comprised 35 healthy individuals or patients suffering from diseases other than tuberculosis.
Results: The tests showed that there was a significant difference in antibody levels between the patients with active
pulmonary disease, extrapulmonary tuberculosis and leprosy in comparison with the control group (p<O.OOl l. The
sensitivities of the two tests together for proven pulmonary tuberculosis were 100% and 95.7% at 1.0-1.5 and> 1.6 EIA
cut-off points respectively, while the specificities were 88.5% and 100% at the same cut-off points. The sensitivities for
extrapulmonary tuberculosis were 71.4% and only 51.4% at 1.0-1.5 and >1.6 EIA cut-off points. The test was positive in
30 (21.9%) ofthe 137 suspected patients, while 43 (31.4%) had an equivocal result and the remaining 64 (47.7%) suspects
were definitely negative. There was again a significant difference in positivity rates between suspects and the control
group.
Conclusions: Omega IgG test is useful in the serodiagnosis of active pulmonary tuberculosis and leprosy, but less
sensitive in extrapulmonary disease, particularly in children. Equivocal results may only add to the evidence of
tuberculosis in early or minimal disease.
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INTRODUCTION
Tuberculosis is currently very highly rated as an im-
portant infectious disease worldwide. In countries with
a significant HIV problem it occurs in AIDS, posing a
very serious medical problem [1]. There is therefore a
great need for accurate and rapid laboratory diagnosis.
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The conventional methods of direct sputum examina-
tion and bacteriologic culture used for laboratory
diagnosis of pulmonary tuberculosis are simple but
insensitive or slow. They are generally unhelpful in the
diagnosis of extrapulmonary tuberculosis when the
focus of the disease is unknown or is difficult to access
for the collection of laboratory specimens. Newer
techniques for the rapid diagnosis and identification
of mycobacterial species, such as polymerase chain
reaction (PCR), ligase chain reaction (LCR) and
several other molecular methods, have recently come
into use and have greatly shortened the time needed
for diagnosis of different types of pulmonary myco-
bacterioses. These techniques are, however, of little
value in the diagnosis of extra-pulmonary disease, and
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serology would be considered a more appropriate
approach to diagnosis.
However, as there is a great diversity of antigens
and antibodies to mycobacteria, there has not been any
acceptable standard serologic test for the diagnosis of
tuberculosis. Recently, a specific antigen of 38 kDa
has been identified [1] and has been expressed as a
recombinant in Escherichia coli. Two kits are com-
mercially available and utilize an enzyme immunoassay
(EIA) for IgG antibodies [2]. One of the sets is
Pathozyme TB-Complex for detection of antibodies
to Mycobacterium tuberculosis complex, including M.
tuberculosis, M. bovis and M. qfricanum, and the other is
Pathozyme-Myco for detection ofantibodies to various
Mycobacterium species. This test has produced some
promising results in a study in Pakistan of patients
with smear- and culture-positive tuberculosis, yielding
sensitivity and specificity rates of 79% and 86%
respectively (Omega: unpublished, in--house data on
serologic evaluation ofthe kit in Pakistan patients). This
study was conducted to evaluate the usefulness of this
diagnostic kit in various forms of tuberculosis and
leprosy in the United Arab Emirates.
PATIENTS AND METHODS
The study was carried out by two laboratories in the
cities of Dubai and AI Ain, the United Arab Emirates
(UAE), between April 1995 and June 1996. The
study was conducted on serum specimens received in
the laboratory on the initial visits of the reported
patients before they were fully diagnosed. Some of the
patients had sputum or other laboratory specimens for
mycobacterial smears and culture, but some patients
(suspects) had only clinical and radiologic evidence for
the suspected diagnosis.
Sera were obtained from a total of 247 persons,
comprising 58 patients who were culture positive for
M. tuberculosis complex or had acid- and alcohol-fast
bacilli (AAFB) visualized in stained preparations, six
proven but recently treated cases, 11 proven leprosy
cases, 137 cases clinically or radiologically suspected but
negative on culture and or microscopy, or from whom
specimens for bacteriology were unavailable, and 35
controls who were either healthy individuals or patients
with diseases not suspected to be tuberculosis. All
patients and controls were adults, except for 13 children
with proven extrapulmonary infections by M. tuber-
culosis (including BCG). Sera were tested in batches at
convenient intervals. The EIA test was performed in
parallel and in duplicate, according to the manu-
facturer's protocol, using the two antigens Pathozyme
TB-Complex for M. tuberculosis complex IgG and
Pathozyme-Myco for other Mycobacterium species.
These kits were kindly supplied by Omega Diagnostics
Ltd, Alloa, Scotland. Serum was diluted 1/100 with the
serum diluent, and the kit components were brought
to room temperature before the start of the procedure.
Each serum and three controls were tested in duplicate.
One hundred microliters of the diluted serum and
control sera were dispensed into appropriate microtiter
wells coated with mycobacterial antigen. The plates
were sealed and incubated at 3rc for 60 min. The
plates were then washed three times, automatically with
the kit's diluted wash buffer. They were dried by
shaking and inverting them on absorbent paper, taking
biohazard precautions. To each well 100 J-lL of con-
jugate was added, and the plates were covered, shaken
gently for 15 s and then reincubated for another 30
min. The wash procedure was repeated, and 100 J-lL
of 3,3',5,5' -tetramethylbenzidine (TMB) substrate was
then added. After gentle shaking the plate was re-
incubated for 15 min. The reaction was stopped by
addition of 100 J-lL stop solution to each well. A change
from blue to yellow indicated the presence ofantibodies.
The ELISA plate reader was blanked on air and the
absorbence immediately read at 450 nm. The EIA
absorbency was recorded and the absorbency figure of
the test specimen was divided by that of the low
positive control and the result: expressed as an EIA
index. An EIA index of< 0.99 was considered negative,
1.0-1.5 as equivocal, and equal or >1.6 as positive.
The two parallel results recorded for Pathozyme TB-
Complex and Pathozyme-Myco were compared and
the higher reading of the two was used as the final
diagnostic value. Chi-squared analysis was performed
to test the differences in the different groups and
clinical situations.
RESULTS
Table 1 shows the EIA indices obtained in the two tests
for the 247 subjects studied. A comparison of the two
tests shows that the Pathozyme-Myco test produced
more positives and showed higher levels of antibodies
than the Pathozyme TB-Complex. Among the 58
patients with tuberculosis, 48 showed antibodies in
both tests, and Pathozyme-Myco identified 47 of these,
while Pathozyme TB-Complex identified only 27.
Among the 83 people with an EIA index > 1.6,
Pathozyme-Myco was positive in 81, against only 20
with Pathozyme TB-Complex. All 11 leprosy cases
were positive with Pathozyme-Myco, while only six
were positive in Pathozyme TB-Complex.
Table 2 summarizes the differences between dif-
ferent conditions with positive results from either test.
In the control group of 35 normal subjects or patients
not suspected to have tuberculosis, there was none with
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Table 1 ErA results in the different groups studied
'Includes smear positive without confirmation; bincludes BCG;
'without laboratory evidence,
Table 2 Mycobacterial EIA indices with either test in the
study subjects
an antibody level of 1.6 or more, while there were four
equivocal positive results, three of which were in the
Pathozyme-Myco test, On the other hand, all 23
The development of a reliable, sensItIve and specific
serologic test for tuberculosis and other mycobacterial
infections has proved difficult. Recent evaluation of
ELISA assays based on the A60 antigen has found these
lacking [3]. The discovery of the 38-kDa lipoprotein
antigen, which is more specific, has given new hope in
serodiagnosis [4].
Using one of these 38-kDa antigens, the most
recent commercially developed kits (Omega diag-
nostics), for the diagnosis of all types of mycobacterial
diseases, the data obtained show that there is not, as yet,
a very sensitive serologic test available. With either of
the positive parallel tests and the lower cut-off point,
31 (88.7%) of the control group were negative and only
four (11.3%) had equivocal results. On the other hand,
all the patients (100%) with evidence of active pul-
monary tuberculosis and leprosy were positive and the
difference from the control group was higWy significant
(p<O.OOl). This type of high sensitivity for smear-
positive patients has been demonstrated before [5].
Another recent evaluation reported a similar result
in 36 cases of smear-proven or histologically proven
extrapulmonary tuberculosis (Omega: unpublished in-
house data on serologic evaluation of the kit in Pakistan
patients).
The results are, however, different in the patients
with laboratory evidence of extrapulmonary infection,
where the sensitivity is 71.4% for the 35 cases at the
patients with laboratory evidence of pulmonary tuber-
culosis had antibody levels of > 1.0-1.5, while 22
(95.7%) had antibody levels of >1.6. The difference
between the two groups is statistically significant at the
two levels of EIA positivity. Twenty-five (71.4%) of
35 cases with laboratory evidence of extrapulmonary
infection with M. tuberculosis complex were positive
at one or both levels, but only 18 (51.4%) were un-
equivocal. Five of the seven equivocal results were in
children, with tuberculous meningitis, cold abscess,
cryptic marrow infection and lymphadenitis. There
were 10 patients who were negative. These included
mainly children with BeG abscesses and some adults
with urinary tract problems and doubtful AAFBs seen
on microscopy. Ten of 11 cases with leprosy showed
antibody levels of 1.0-1.5, while nine had unequivocal
results of >1.6. Four of the six previously treated
tuberculosis cases had antibodies with EIA of>1.6, one
was equivocal, and the other, who had been treated for
renal tuberculosis, was negative. Of the 137 suspected
tuberculosis cases (without laboratory evidence) tested,
30 (21.9%) had significant antibodies, while the rest
were equivocal or negative.
DISCUSSION
22
18
4
9
30
o
1.6+
1
7
1
2
43
4
1.0-1.5
EIA index
o
10
1
°64
31
0,0-0,99
+ 4
± ± 1
1 6
+ ± 5
+ 4
± ± 1
± 1 11
+ + 2
+ ± 3
+ 24
+ 1
± 18
± 19
± ± 6
64 137
31
± 3
± 1 35
+ + 4
+ ± 7
+ 7
± 7
10 35
+ + 10
± + 2
+ ± 2
+ 7
+ 1
± ± 1
o 23
23
35
6
11
137
35
Myco TB-Comp Number Total
Numbers
tested
Conditions or
sources of serum
Pulmonary tuberculosis'
Extrapulmonary TB b
Treated tuberculosis
Leprosy
Suspected tuberculosis'
Controls
ElAindices: +=>1.6, ±=1.00-1.5, -=0,0-0,99,
'Includes smear positive without confirmation; bincludes BCG;
'without laboratory evidence,
Myco=Pathozyme-Myco; TB-Comp =Pathozyme TB-Complex,
Controls
Treated tuberculosis
Leprosy
Suspected tuberculosis'
Extrapulmonary
tuberculosis "b
Pulmonary tuberculosis'
Conditions
Nsanze et al: Serodiagnosis of tuberculosis and leprosy by enzyme immunoassay 239
higher cut-off point. The combined results of all
patients with laboratory evidence of tuberculous in-
fection give a sensitivity rate of 82.8%, including
the equivocal diagnosis, and 62.5% for unequivocal
diagnosis. The overall picture, however, is dependent
on the proportion of pulmonary to other forms of
tuberculosis.
Although antibody detection appears to be more
frequent and of higher level in sputum-positive than in
sputum-negative patients, factors other than bacterial
load per se may play a role and could be of clinical
relevance. In view of the intracellular nature of the
mycobacteria, and because more seronegative patients
are paucibacillary, it seems unlikely that antibody trap-
ping in circulating immune complexes could explain
this phenomenon [5].
In the suspected tuberculosis group, a lower posi-
tivity rate of nearly 20% and equivocal results of 47.3%
were observed. This was significantly higher than in the
control group. Although this group was not followed
up for the final diagnosis, and response to anti-
tuberculous therapy was not recorded, the results of the
test might be useful as additional evidence for or against
the diagnosis of tuberculosis.
The main serologic problem in other earlier studies
was the use of crude reagents containing a great
diversity of antigens, which detected antibodies at
unacceptably high antibody frequency in healthy
subjects. The recently introduced individual antigens,
such as 38-kDa protein antigen, provide a contrast, and
the main diagnostic obstacle is their lack of detection
of low antibody levels in 20-30% of tuberculosis
patients. However, this does not seem to be the
problem in our study, as low antibody levels were
detected in nearly all cases of disease. The 38-kDa
antigen has been shown to be the most immunogenic,
and now allows specific antibodies to mycobacteria to
be assayed [6,7]. The serologic immunodominance
of this antigen in tuberculosis was recently confirmed
by Western blot and various monoclonal antibody
tests [8].
The interpretation of the results and setting of the
cut off-point are common difficulties in serodiagnosis.
Serodiagnosis should be compared to standard chest
radiography and sputum microscopy with bacteriologic
culture. It is well known that immunoassays have
not yet achieved higher levels of sensitivity under
conditions of high specificity. V,le have suggested two
levels of EIA index cut-off points, one for definite
positive diagnosis, in which there are no false positives,
and another level for equivocal results, which is very
highly sensitive but may have false positives so that
patients with this result need more evaluation. The
value of parallel testing with the two antigens maxi-
mizes on positivity but might not be cost beneficial in
view of the sensitivity of Pathazyme-Myco alone. This
is surprising; there is no easy explanation why Patho-
zyme-Myco is more frequently positive in tuberculosis
than Pathozyme TB-Complex.
In view of the epidemiologic importance of
infectious pulmonary tuberculosis and its transmission
to healthy susceptible contacts, serologic screening of
populations at high risk in endemic areas should be
considered. This test could also be of some additional
value in the diagnosis of extrapulmonary tuberculosis.
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